Gene Therapy entity AavantiBio has launched after $107 million financing from life science investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, and Sarepta Therapeutics, according to Benzinga. Private financing includes a $15 million equity investment from Sarepta.
- AavantiBio will focus on transforming the lives of patients with rare genetic diseases.
- AavantiBio will pursue a diversified gene therapy, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic dysfunction of the cardiac and central nervous system.
- AavantiBio will maintain strong ties with the University of Florida’s Powell Gene Therapy Center.
Sarepta Therapeutics Inc. stock is gaining. SRPT: NASDAQ is up 0.63%